NEW YORK--(BUSINESS WIRE)--Bioenvision, Inc. (NasdaqGM:BIVN) announced today it has filed a clinical trial authorization (CTA) to begin two Phase I studies of clofarabine gel for the treatment of psoriasis, a disease that affects an estimated 125-million people worldwide.
